Trial Profile
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir; Emtricitabine/tenofovir alafenamide
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms INFE 5305
- Sponsors Gilead Sciences
- 06 Mar 2024 Results analyzing the effect of ART on selected biomarkers of inflammation and immune activation presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
- 26 Oct 2022 Results of pooled analysis from Study 1489 and Stduy 1490 assessing 96-week (W) outcomes on bictegravir/emtricitabine/tenofovir alafe-namide (B/F/TAF) in an open-label extension (OLE) that followed144W of blinded DTG-based treatment in two phase III studies ofPWHIV initiating treatment presented at the 16th International Congress on Drug Therapy and HIV Infection
- 24 Oct 2022 According to a Gilead Sciences media release, results from this trial were presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022).